I ensure that our growing fleet of PET cameras provides excellent image quality and accuracy. MSK currently has 13 cameras, with four more soon to follow. My responsibilities include overseeing the quality assurance and calibration procedures. I also establish the data acquisition and reconstruction protocols for studies involving both standard and exotic radionuclides.
My research interests include pharmacokinetic modeling, parametric image generation, PET data acquisition modeling and reconstruction, data mining, and radionuclide therapy. In addition to consulting on and performing data analysis for several ongoing clinical trials, I have received funding from the National Cancer Institute to develop a novel form of radionuclide therapy. This treatment, an Auger electron-emitting androgen analogue, will be used for people with castration-resistant prostate cancer.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Bradley Beattie discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.
View all disclosures